This article covers Lu-177 PSMA therapy - a radioligand treatment for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). If you are exploring treatment for neuroendocrine tumors, the DOTATATE track on this site covers that separately.
For most international patients, the cost gap is the key reason for traveling to India for Lu-177 PSMA therapy. A single cycle in India may run between INR 125,000 and INR 250,000 - roughly USD 1,500 to USD 3,000 at 2024 exchange rates - while comparable treatment in the United States or Germany costs far more. Whether making that journey makes sense depends on three things: whether you are eligible, whether you are fit to travel, and whether the therapy is available closer to home.
What Is Lu-177 PSMA Therapy?
Lutetium Lu-177 vipivotide tetraxetan - sold as Pluvicto - is a radioligand therapy (RLT) approved for men with mCRPC. PSMA stands for prostate-specific membrane antigen. Many prostate cancer cells carry large amounts of this protein on their surface. The drug attaches a radioactive atom to a molecule that seeks out PSMA-expressing cells. When it binds, the radiation reaches the tumor closely, which reduces dose to most of the surrounding healthy tissue.
The VISION trial tested this approach in men with PSMA-positive mCRPC who had already received an androgen receptor pathway inhibitor and taxane-based chemotherapy. It found that the therapy, combined with standard care, showed a median overall survival of 15.3 months, compared with 11.3 months in the group receiving standard of care alone - a hazard ratio of 0.62. The US Food and Drug Administration approved lutetium Lu-177 vipivotide tetraxetan in March 2022 based on these results.
India has an advantage in this field. The country produces lutetium-177 domestically through its Board of Radiation and Isotope Technology (BRIT), part of the Department of Atomic Energy. This keeps per-cycle costs well below those in countries where the radiopharmaceutical must be imported at commercial prices.
What Does Lu-177 PSMA Therapy Cost in India?
A peer-reviewed study on Lu-177 PSMA therapy in India found that one cycle using domestically produced lutetium - including the labelled radiopharmaceutical, standard investigations, and hospital admission - costs approximately INR 125,000. When imported lutetium is used instead, the per-cycle cost is roughly INR 250,000.
A standard course involves up to six cycles, each spaced approximately six weeks apart. At the domestic supply rate, a full course totals around INR 750,000 - approximately USD 9,000 at 2024 exchange rates. At the imported lutetium rate, the total is roughly INR 1,500,000 - approximately USD 18,000.
These figures cover the radiopharmaceutical and hospital stay. They do not include the PSMA-PET scan needed to confirm eligibility before treatment begins, blood monitoring between cycles, flights, or accommodation in India during the treatment period. Patients staying in India for the full seven-month course need to plan for long-stay living costs. Patients flying home between cycles need to budget for multiple round-trip airfares on top of those medical costs.
For a full breakdown of what international patients pay across each cost category, see our guide to Lu-177 PSMA therapy cost in India for international patients.
How Does the Cost of Lu-177 PSMA Therapy Compare by Country?
| Factor | India | Germany / Western Europe | United States |
|---|---|---|---|
| Cost per cycle | INR 125,000-250,000 (USD 1,500-3,000, 2024) | Varies significantly by center; contact the hospital directly for a written quote before planning travel | Significantly higher than India; typically requires insurance coverage or a negotiated self-pay arrangement |
| Full-course estimate (6 cycles) | INR 750,000-1,500,000 (USD 9,000-18,000, 2024) | Contact treating center; the radiopharmaceutical cost alone is much higher than Indian domestic costs | Contact treating center; full-course costs are substantially higher than in India |
| Regulatory approval | Available; domestically produced Lu-177 via BRIT | EMA-approved; reimbursement varies by country and health insurance plan | FDA-approved since March 2022; insurance coverage varies by indication and plan |
| PSMA-PET scan access | Available at major tertiary centers in metropolitan cities | Available at most major oncology and nuclear medicine centers | Available; 68Ga-PSMA-11 is FDA-approved as the companion diagnostic |
| Access for GCC, Africa, and South Asia patients | Yes - major Indian cities have multiple experienced nuclear medicine departments | Accessible with visa and financial planning; longer travel distance for most source markets | Accessible but requires a US visa, significantly higher costs, and complex insurance navigation |
India cost data: peer-reviewed PubMed Central publication on Lu-177 PSMA therapy in India (2024). Germany and United States figures reflect qualitative comparisons based on published health-economic literature; contact treating centers directly for written cost estimates before making travel plans.
The cost difference between India and Western countries is large. For patients from the GCC, sub-Saharan Africa, Bangladesh, Nepal, or Sri Lanka - where the therapy is not routinely approved - India is often the only path to treatment. Germany and the United States are available for patients who can afford them and have insurance. For most international patients seeking affordable access with experienced doctors, India is the practical choice.
Do You Qualify Before You Book the Flight?
Eligibility for Lu-177 PSMA therapy depends entirely on imaging. The VISION trial enrolled patients with at least one PSMA-positive lesion on a 68Ga-PSMA-11 PET-CT scan and no PSMA-negative metastatic visceral lesion - meaning the cancer must express PSMA at sufficient levels on imaging for the therapy to reach it effectively. Research comparing eligibility criteria across the major radioligand therapy trials shows that many mCRPC patients do not meet this imaging threshold. Not every person with advanced prostate cancer will qualify.
Standard eligibility also requires prior treatment with an androgen receptor pathway inhibitor and taxane-based chemotherapy, though access criteria are evolving. Kidney function, bone marrow reserve, and general performance status are all reviewed before each cycle. Significant impairment in any of these areas may make treatment unsafe even where PSMA expression on imaging is adequate.
If you have your PSMA-PET scan and recent records ready, you can request a Lu-177 eligibility review through Art of Healing Cancer before you make any travel plans. If the review finds that Lu-177 PSMA therapy is not right for you, the team can discuss what other treatments may help your situation.
For a plain-language guide to what your scan report means, see what your PSMA-PET results mean for Lu-177 eligibility.
What Does the Treatment Schedule Mean in Practice?
A full six-cycle course spans roughly 30 weeks from the first infusion to the last. Cycles are given every six weeks. That schedule creates a real question: stay in India throughout the full course, or fly home between cycles?
Staying in India throughout has clear advantages. It avoids multiple long-haul flights and the physical toll they bring. It avoids worrying about radiation safety during air travel in the days right after each infusion. And it keeps you near the treating team if a problem arises between cycles - monitoring for low blood counts, fatigue, or dry mouth (one of the more commonly reported side effects) is easier when you are not thousands of kilometers away.
Flying home between cycles works better for patients within a manageable flight distance, with strong support at home, and where accommodation costs in India are less than multiple round-trip airfares. Patients from neighboring South Asian countries sometimes find this workable. Patients traveling from the GCC or parts of Africa often find it more practical and less draining to complete two or three consecutive cycles before returning home.
For practical guidance on managing radiation safety when traveling, see our article on how to travel safely between Lu-177 PSMA cycles.
When Does Staying Home Make More Sense?
Traveling to India for Lu-177 PSMA therapy is not the right answer for every patient. Here's when a different choice may serve you better.
- The therapy is available and covered where you live. In countries with reimbursed access to Lu-177 PSMA therapy - parts of Europe, Australia, or Canada - try that option first before planning international travel. The savings from India may not justify the journey if home-country treatment is available.
- You have not yet had a PSMA-PET scan. Traveling without first confirming PSMA eligibility is a serious financial risk. Arrange the scan first and share results remotely before committing to any trip.
- Your fitness to travel has declined significantly. Severe bone pain, marked fatigue, or serious heart or lung problems may make long-haul flights unsafe. Your oncologist at home needs to assess this honestly before you plan any journey.
- Your kidney function is significantly impaired. Lu-177 PSMA therapy leaves your body through the kidneys, and serious kidney impairment may disqualify you from treatment regardless of PSMA expression. This must be reviewed before traveling.
- You are mid-way through another active systemic treatment. Some therapies require a washout period before Lu-177 PSMA can begin safely. Discuss timing with your oncologist before booking any flights.
Steps to Take Before Booking Your Trip
If India seems right for you and you believe you may be a candidate, take these steps in order before committing to travel.
- Get a PSMA-PET scan if you have not had one. No eligibility assessment is possible without it.
- Gather your full medical records - pathology results, previous treatment history, recent PSA values, and any existing imaging reports.
- Share your records and scan with a nuclear medicine team in India for a remote eligibility review. Most experienced centers can do this before you arrive.
- Request written cost estimates covering the radiopharmaceutical, hospital fees, and any imaging or monitoring required during your stay in India.
- Plan your accommodation and logistics for the treatment period - either for the full course or for the number of cycles you plan to complete before going home.
- Confirm your fitness to travel with your oncologist at home before finalizing any plans.
To begin the process, send your PSMA-PET results and medical records through the Lutetium Therapy contact form for a clinical review. If Lu-177 PSMA therapy is not suitable for your case, the team can discuss what other treatments might help.
When to Talk to Your Doctor
Talk to your oncologist if your prostate cancer has continued growing despite hormone therapy and chemotherapy, if you are unsure whether your PSMA-PET scan results make you eligible for Lu-177 PSMA therapy, or if you are considering a trip to India for treatment and need help understanding what that journey would involve for your situation. A second opinion from a nuclear medicine specialist can help if your current team has limited experience with radioligand therapy.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
How much does Lu-177 PSMA therapy cost in India for international patients?
A peer-reviewed study indexed on PubMed Central found that one cycle of Lu-177 PSMA therapy in India costs approximately INR 125,000 when domestically produced lutetium is used, and around INR 250,000 when imported lutetium is supplied. A standard treatment course involves up to six cycles. At the domestic supply rate, a full course totals around INR 750,000 - approximately USD 9,000 at 2024 exchange rates. These figures cover the radiopharmaceutical, hospital admission, and standard tests. Travel, accommodation, and PSMA-PET scanning costs are separate and need to be budgeted for on top of the medical fees.
Do I need a PSMA-PET scan before traveling to India for Lu-177 PSMA therapy?
Yes. Eligibility depends entirely on this scan. Your cancer must show sufficient PSMA expression on a 68Ga-PSMA-11 PET/CT scan for treatment to be appropriate. Traveling to India without first confirming eligibility through a remote review is a significant financial risk. Most experienced centers in India can review your scan and records remotely before you commit to any travel, and this step should happen before you book flights.
How many trips to India will I need for a full course of Lu-177 PSMA therapy?
A full course involves up to six cycles spaced approximately six weeks apart - roughly seven months from the first infusion to the last. Some patients stay in India throughout the entire course to avoid repeated long-haul travel. Others fly home between cycles when the travel distance and cost make that practical. Patients from neighboring South Asian countries sometimes manage multiple shorter trips. Patients traveling from the GCC or parts of Africa often find it more manageable to complete two or three consecutive cycles before returning home.
What happens if I travel to India and am found to be ineligible on arrival?
This is a real risk for any patient who has not had a remote eligibility review before booking travel. If imaging or blood work in India shows that the treatment is not appropriate - because PSMA expression is insufficient, kidney function is too low, or another safety concern is identified - the treating team should discuss what alternatives may exist. The best way to avoid an unnecessary and costly trip is to share your PSMA-PET scan and medical records with an Indian nuclear medicine team for remote review before booking any flights.
Is the quality of Lu-177 PSMA therapy in India the same as in the US or Germany?
The radiopharmaceutical and the underlying science are the same. India uses lutetium-177 produced through its domestic Board of Radiation and Isotope Technology and at established nuclear medicine centers. The level of experience can vary between hospitals, so choosing a center with a dedicated theranostics program and a track record in radioligand therapy is important. A remote consultation before traveling can help you assess whether a specific center and team are appropriate for your case.
Will my health insurance cover Lu-177 PSMA therapy costs in India?
This depends on your specific policy and country of residence. Many international insurance plans do not cover treatment abroad, or they have specific exclusions for nuclear medicine or experimental therapies. Some patients from Gulf countries have arranged pre-authorization through employer health plans or national programs, but this is not standard practice. Contact your insurer directly before making any travel plans, explain exactly what treatment is planned and where, and get any coverage commitment in writing before you commit to traveling.
